Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion

Journal of Neurochemistry

Volumn 95, Issue 1, 2005, Pages 79-88

  Gal, Shunit ^a   Zheng, Hailin ^b   Fridkin, Mati ^b   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Alzheimer's disease; Dopamine; Iron chelator; Monoamine oxidase A and B inhibitor; Multifunctional drugs; Neuroprotection; Parkinson's disease; Serotonin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 5 (N METHYL N PROPARGYLAMINOMETHYL) 8 HYDROXYQUINOLINE; 5 (N PROPARGYLAMINOMETHYL) 8 HYDROXYQUINOLINE; 5 [4 (2 HYDROXYETHYL)PIPERAZIN 1 YLMETHYL] 8 HYDROXYQUINOLINE; 5 HYDROXYINDOLEACETIC ACID; DEFEROXAMINE MESYLATE; DOPAMINE; HOMOVANILLIC ACID; IRON CHELATING AGENT; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; N PROPARGYLAMINE; NORADRENALIN; SEROTONIN; UNCLASSIFIED DRUG; VK 28;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBELLUM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; HIPPOCAMPUS; HYPOTHALAMUS; IC 50; IN VIVO STUDY; INTESTINE; LIVER; MALE; NEUROPROTECTION; NONHUMAN; NORADRENALIN RELEASE; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMINES; ANIMALS; BRAIN; CORPUS STRIATUM; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; HYDROXYQUINOLINES; HYPOTHALAMUS; IRON CHELATING AGENTS; MALE; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE INHIBITORS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE, SECONDARY;

EID: 25644452043     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2005.03341.x     Document Type: Article

References (65)

1. Abu-Raya S., Blaugrund E., Trembovler V., Shilderman-Bloch E., Shohami E. and Lazarovici P. (1999) Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. J. Neurosci. Res. 58, 456-463.
2. Acuna-Castroviejo D., Coto-Montes A., Gaia Monti M., Ortiz G. G. and Reiter R. J. (1997) Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci. 60, PL23-29.
3. Akao Y., Maruyama W., Shimizu S., Yi H., Nakagawa Y., Shamoto-Nagai M., Youdim M. B., Tsujimoto Y. and Naoi M. (2002) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)- aminoindan. J. Neurochem. 82, 913-923.
4. Bar-Am O., Yogev-Falach M., Amit T., Sagi Y. and Youdim M. B. (2004) Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J. Neurochem. 89, 1119-1125.
5. Ben-Shachar D. and Youdim M. B. H. (1990) Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction. J. Neural Transm. Suppl. 29, 251-258.
6. Ben-Shachar D., Eshel G., Finberg J. P. and Youdim M. B. (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56, 1441-1444.
7. Binda C., Hubalek F., Li M., Herzig Y., Sterling J., Edmondson D. E. and Mattevi A. (2004) Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J. Med. Chem. 47, 1767-1774.
8. Birkmayer W., Riederer P., Ambrozi L. and Youdim M. B. (1977) Implications of combined treatment with 'Madopar' and 1-deprenil in Parkinson's disease. A long-term study. Lancet 1, 439-443.
9. Blandini F., Armentero M. T., Fancellu R., Blaugrund E. and Nappi G. (2004) Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp. Neurol. 187, 455-459.
10. Cadet J. L., Katz M., Jackson-Lewis V. and Fahn S. (1989) Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res. 476, 10-15.
11. Dexter D. T., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P. and Marsden C. D. (1989a) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 1830-1836.
12. Dexter D. T., Carter C. J., Wells F. R., Javoy-Agid F., Agid Y., Lees A., Jenner P. and Marsden C. D. (1989b) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381-389.
13. Finberg J. P. and Youdim M. B. (2002) Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 43, 1110-1118.
14. Finberg J. P., Lamensdorf I., Weinstock M., Schwartz M. and Youdim M. B. (1999) Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv. Neurol. 1999, 495-499.
15. Fraucheux B. A., Martin M. E., Beaumont C., Hauw J. J., Agid Y. and Hirsch E. C. (2003) Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 86, 1142-1148.
16. Gerlach M., Ben-Shachar D., Riederer P. and Youdim M. B. H. (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 793, 793-807.
17. Green A. R., Mitchell B. D., Tordoff A. F. and Youdim M. B. (1977) Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol. 60, 343-349.
18. Grunblatt E., Mandel S., Jacob-Hirsch J. et al. (2004) Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural Transm. 111, 1543-1573.
19. Heikkila R. E., Terleckyj I. and Sieber B. A. (1990) Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP. J. Neural Transm. Suppl. 32, 217-227.
20. Huang W., Chen Y., Shohami E. and Weinstock M. (1999) Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur. J. Pharmacol. 366, 127-135.
21. Jellinger K. A. (1999) The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14, 115-140.
22. Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P. and Youdim M. B. H. (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Park. Dis. Dement. Sect. 2, 327-340.
23. Jellinger K., Kienzel E., Rumpelmair G., Riederer P., Stachelberger H., Ben-Shachar D. and Youdim M. B. H. (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J. Neurochem. 59, 1168-1171.
24. Jenner P. and Olanow C. W. (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47, S161-S170.
25. Kalir A., Sabbagh A. and Youdim M. B. (1981) Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br. J. Pharmacol. 73, 55-64.
26. Kaur D., Yantiri F., Rajagopalan S. et al. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37, 899-909.
27. Keller R., Oke A., Mefford I. and Adams R. N. (1976) Liquid chromatographic analysis of catecholamines routine assay for regional brain mapping. Life Sci, 19, 995-1003.
28. Lamensdorf I., Youdim M. B. and Finberg J. P. (1996) Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J. Neurochem. 67, 1532-1539.
29. Lan J. and Jiang D. H. (1997a) Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Transm. (Budapest) 104, 469-481.
30. Lan J. and Jiang D. H. (1997b) Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J. Neural Transm. 104, 649-660.
31. Levine S. M. and Chakrabarty A. (2004) The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann. N. Y. Acad. Sci. 1012, 252-266.
32. Mandel S., Weinreb O., Amit T. and M. B. H. Y. (2004) Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J. Neurochem.
33. Maruyama W., Yamamoto T., Kitani K., Carrillo M. C., Youdim M. and Naoi M. (2000) Mechanism underlying anti-apoptotic activity of a (-) deprenyl-related propargylamine, rasagiline. Mech. Ageing Dev. 116, 181-191.
34. Maruyama W., Akao Y., Youdim M. B. and Naoi M. (2002) Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J. Neural Transm. Suppl. 60, 171-186.
35. Maruyama W., Weinstock M., Youdim M. B., Nagai M. and Naoi M. (2003) Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)- aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci. Lett. 341, 233-236.
36. Melamed E., Youdim M. B., Rosenthal J., Spanier I., Uzzan A. and Globus M. (1985) In vivo effect of MPTP on monoamine oxidase activity in mouse striatum. Brain Res. 359, 360-368.
37. Mochizuki H., Imai H., Endo K., Yokomizo K., Murata Y., Hattori N. and Mizuno Y. (1994) Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci. Lett. 168, 251-253.
38. O'Carroll A. M., Fowler C. J., Phillips J. P., Tobbia I. and Tipton K. F. (1983) The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn-Schmiedebergs Archives of Pharmacology 322, 198-202.
39. Oestreicher E., Sengstock G. J., Riederer P., Olanow C. W., Dunn A. J. and Arendash G. W. (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660, 8-18.
40. Parkinson Study Group. (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol. 62, 241-248.
41. Perry T. L., Yong V. W., Clavier R. M., Jones K., Wright J. M., Foulks J. G. and Wall R. A. (1985) Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. 60, 109-114.
42. Rascol O., Brooks D. J., Melamed E., Oertel W., Poewe W., Stocchi F., Tolosa E. and LARGO study Group. (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365, 947-954.
43. Riederer P., Sofic E., Rausch W. D., Schmidt B., Reynolds G. P., Jellinger K. and Youdim M. B. H. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
44. Smith M. A., Harris P. L., Sayre L. M. and Perry G. (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl Acad. Sci. USA 94, 9866-9871.
45. Speiser Z., Mayk A., Eliash S. and Cohen S. (1999) Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J. Neural Transm. 106, 593-606.
46. Tatton W., Chalmers-Redman R. and Tatton N. (2003) Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J. Neural Transm. 110, 509-515.
47. Temlett J. A., Landsberg J. P., Watt F. and Grime G. W. (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J. Neurochem. 62, 134-146.
48. Tipton K. F. and Youdim M. B. H. (1983) The assay of monoamine oxidase activity, in Methods in Biogenic Amine Research. (eds H. Parvez and T. Nagatsu), pp. 441-465. Elsevier, Amsterdam.
49. Todorich B. M. and Connor J. R. (2004) Redox metals in Alzheimer's disease. Ann. N. Y. Acad. Sci. 1012, 171-179.
50. Weinreb O., Bar-Am O., Amit T., Chillag-Talmor O. and Youdim M. B. (2004) Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 Family members. FASEB J. 18, 1471-1473.
51. Weinstock M., Bejar C., Wang R. H., Poltyrev T., Gross A., Finberg J. P. and Youdim M. B. (2000) TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural Transm. Suppl. 60, 157-169.
52. Weinstock M., Gorodetsky E., Wang R. H., Gross A., Weinreb O. and Youdim M. B. (2002) Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits. Neuropharmacology. 43, 999-1005.
53. Yogev-Falach M., Amit T., Bar-Am O. and Youdim M. B. (2003) The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J. 17, 2325-2327.
54. Youdim M. B. H. (2003) Rasagiline; An antiparkinson drug with neuroprotective activity. Expert Rev. Neurotherapeutics 3, 737-749.
55. Youdim M. B. H. and Buccafesco J. (2005) Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 26, 27-36.
56. Youdim M. B. H. and Riederer P. (2004) Iron in the brain, normal and pathological, in Encyclopedia of Neuroscience. Elsevier Science.
57. Youdim M. B. and Weinstock M. (2004) Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology 25, 243-250.
58. Youdim M. B., Ben-Shachar D. and Riederer P. (1993) The possible role of iron in the etiopathology of Parkinson's disease. Mov. Disord. 8, 1-12.
59. Youdim M. B., Gross A. and Finberg J. P. (2001a) Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 132, 500-506.
60. Youdim M. B., Wadia A., Tatton W. and Weinstock M. (2001b) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. N. Y. Acad. Sci. 939, 450-458.
61. Youdim M. B., Fridkin M. and Zheng H. (2004a) Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J. Neural Transm. 111, 1455-1471.
62. Youdim M. B., Stephenson G. and Ben Shachar D. (2004b) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. N. Y. Acad. Sci. 1012, 306-325.
63. Zecca L., Youdim M. B., Riederer P., Connor J. R. and Crichton R. R. (2004) Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5, 863-873.
64. Zheng M., Weiner L. M., Bar-Am O., Epsztejn M., Cabantchik I., Warshawsky A., Youdim M. B. H. and Fridkin M. (2005a) Design, synthesis and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in neurodegenerative diseases. Bioorg. Med. Chem. 13, 773-783.
65. Zheng H., Gal S., Weiner L. M., Bar-Am O., Warshawsky A., Fridkin M. and Youdim M. B. H. (2005b) Novel multifunctional neuroproctective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases, in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 95, 68-78.